TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12373694

Group type: EXPERIMENTAL
Intervention: Paravertebral somatic nerve block (PVB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Peripheral block (PB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 46

Group type: COMPARATOR
Intervention: PB
Number of subjects: 46
Study: 9988787

Group type: EXPERIMENTAL
Intervention: Cold-knife conization
Number of subjects: 180

Group type: COMPARATOR
Intervention: Loop electrosurgical excision procedure
Number of subjects: 180
Study: 7494110

Group type: EXPERIMENTAL
Intervention: Prednisolone plus a beta‐lactamase stable antibiotic for 10 days, with responders receiving an additional six weeks of chemoprophylaxis.
Number of subjects: 122

Group type: COMPARATOR
Intervention: No medication (Control group).
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Prednisolone plus a beta‐lactamase stable antibiotic.
Number of subjects: 122
Study: 2176898

Group type: EXPERIMENTAL
Intervention: Peanut oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medium chain triglyceride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peanut oil and medium chain triglyceride
Number of subjects: 0
Study: 7439263

Group type: EXPERIMENTAL
Intervention: Oral administration of ketoprofen (capsule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of ketoprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal administration of ketoprofen (suppository)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ketoprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated oral administration of ketoprofen (50 mg q.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single oral dose of ketoprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31815790

Group type: EXPERIMENTAL
Intervention: Surrogate endpoints including glomerular filtration rate slope, albuminuria, donor-specific alloantibodies, and histological score at graft protocol biopsies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical multiple primary endpoints using surrogate endpoints.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New clinical endpoints focusing on treatment safety and patient quality of life.
Number of subjects: 0
Study: 31182123

Group type: EXPERIMENTAL
Intervention: eConsult access for 1 year
Number of subjects: 113

Group type: COMPARATOR
Intervention: No access to eConsult (Control)
Number of subjects: 113
Study: 28178008

Group type: EXPERIMENTAL
Intervention: Liquid Nitrogen (LN2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1,1,1,2-tetrafluoroethane (TFE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No additional cooling treatment (Control)
Number of subjects: 24
Study: 25808994

Group type: EXPERIMENTAL
Intervention: CNI-free (everolimus with half-dose EC-MPS 720 mg/day and cyclosporine withdrawal)
Number of subjects: 194

Group type: COMPARATOR
Intervention: CNI (continue cyclosporine with standard EC-MPS)
Number of subjects: 194
Study: 23668026

Group type: EXPERIMENTAL
Intervention: Decoction of invigorating Qi and clearing lung combined with standardized myrtol (300 mg, 3 times a day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standardized myrtol (300 mg, 3 times a day)
Number of subjects: 98
Study: 21030470

Group type: EXPERIMENTAL
Intervention: Sustained seating force during bonding (300 g for 3 seconds, maintained for 40 seconds during curing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Initial seating force (300 g for 3 seconds, no sustained force)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 19472007

Group type: EXPERIMENTAL
Intervention: Shaker exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 19
Study: 17592789

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone (160 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone (mean dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not treating (control)
Number of subjects: 0
Study: 15213497

Group type: EXPERIMENTAL
Intervention: Tricortical screw fixation (2 screws, 3.5-mm each)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Quadricortical screw fixation (1 screw, 4.5-mm)
Number of subjects: 64
Study: 11588528

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg, once daily)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg, once daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9849987

Group type: EXPERIMENTAL
Intervention: Three dose primary schedule (2, 4, 6 months)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Two dose primary schedule (3, 5 months)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Both schedules after booster vaccinations
Number of subjects: 236
Study: 7851356

Group type: EXPERIMENTAL
Intervention: Neostigmine and methyl-atropine administered 2 minutes after rocuronium (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine and methyl-atropine administered at 25% twitch recovery (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmine and methyl-atropine administered at spontaneous recovery (Group A)
Number of subjects: 60
Study: 2577692

Group type: EXPERIMENTAL
Intervention: dilevalol
Number of subjects: 8

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 8
Study: 68454

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) injection of bleomycin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) injection of bleomycin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 110
Study: 30659994

Group type: EXPERIMENTAL
Intervention: 12-week conditional cash transfer intervention followed by a 4-week cognitive-behavioural aftercare group (CCT + AC)
Number of subjects: 600
Study: 26482136

Group type: EXPERIMENTAL
Intervention: Therapeutic Educational System (TES) with Contingency Management (CM) component, earning up to $600 in prizes over 12 weeks for providing drug negative urines and completing web-based cognitive behavior therapy modules.
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care counseling (without TES).
Number of subjects: 255
Study: 25174443

Group type: EXPERIMENTAL
Intervention: Bioline® (albumin-heparin coating)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phisio® (phosphorylcholine polymer coating)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 23740194

Group type: EXPERIMENTAL
Intervention: Triple antioxidant therapy (allopurinol, α-lipoic acid, and nicotinamide)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21610398

Group type: EXPERIMENTAL
Intervention: Workshop training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: On-the-job (OTJ) training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Booster training
Number of subjects: 14
Study: 19843804

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuraxial analgesia
Number of subjects: 0
Study: 16621227

Group type: EXPERIMENTAL
Intervention: Non-dissection of the rectus sheath inferiorly during Pfannenstiel incision
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dissection of the rectus sheath inferiorly during Pfannenstiel incision
Number of subjects: 120
Study: 12736891

Group type: EXPERIMENTAL
Intervention: Constant wearing of multipolar, static magnetic (450G) shoe insoles
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo group wearing similar, unmagnetized device
Number of subjects: 375
Study: 11061537

Group type: EXPERIMENTAL
Intervention: 20 U/kg Escherichia coli endotoxin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6
Study: 9223025

Group type: EXPERIMENTAL
Intervention: L‐NMMA 4.0 mumol/min i.v.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L‐arg (30 mumol/kg‐min i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8
Study: 8335541

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (10 g/kg body wt)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (5 g/kg body wt)
Number of subjects: 23
Study: 2952606

Group type: EXPERIMENTAL
Intervention: Intravenous and intracoronary thrombolysis with transluminal coronary angioplasty
Number of subjects: 127

Group type: COMPARATOR
Intervention: Intravenous and intracoronary thrombolysis without transluminal coronary angioplasty
Number of subjects: 127
Study: 29878035

Group type: EXPERIMENTAL
Intervention: 10 µg vitamin D3/d (400 IU)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 20 µg vitamin D3/d (800 IU)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (0 µg vitamin D3/d)
Number of subjects: 144
Study: 27394029

Group type: EXPERIMENTAL
Intervention: Follow-up antibody testing after RBC transfusions
Number of subjects: 100

Group type: COMPARATOR
Intervention: No follow-up antibody screen or testing too soon (<30 days) after transfusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up testing 30 to 112 days posttransfusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up testing more than 112 days posttransfusion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Testing at both 30 to 112 days and more than 112 days
Number of subjects: 100
Study: 24057100

Group type: EXPERIMENTAL
Intervention: Molecular resonance (MR)‐induced tonsil thermal ablation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard bipolar dissection tonsillectomy
Number of subjects: 62
Study: 22340993

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10mg/kg as a bolus preoperatively followed by 1mg/kg as a maintenance dose intra operatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50
Study: 20206835

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 18319058

Group type: EXPERIMENTAL
Intervention: 10mg ilaprazole
Number of subjects: 21
Study: 16450827

Group type: EXPERIMENTAL
Intervention: Novel nutritional immune formula (NNIF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 12857764

Group type: EXPERIMENTAL
Intervention: Exercise training program (6 months of physical therapy, strength training, and walking followed by 3 months of endurance exercise at 78% of peak heart rate)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control sedentary group
Number of subjects: 46
Study: 10675246

Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 44
Study: 8693765

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 23

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 23
Study: 2003858

Group type: EXPERIMENTAL
Intervention: Ketotifen (6 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6856363

Group type: EXPERIMENTAL
Intervention: Methylphenidate at lower dosages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate at higher dosages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31062264

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 100
Study: 30342551

Group type: EXPERIMENTAL
Intervention: Guanxinjing capsule (GXJ)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27914885

Group type: EXPERIMENTAL
Intervention: Ultrasound assisted percutaneous liver biopsy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Percussion guided technique
Number of subjects: 102
Study: 24608207

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22507611

Group type: EXPERIMENTAL
Intervention: Greater length-for-age
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Greater weight-for-age
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Frequency of daily complementary feeding
Number of subjects: 158
Study: 19850529

Group type: EXPERIMENTAL
Intervention: Standard urotherapy and pelvic floor exercises
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups received pharmacotherapy (anticholinergics or desmopressin) as needed
Number of subjects: 75
Study: 18628671

Group type: EXPERIMENTAL
Intervention: Emotionally negative words perceived by the left visual cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotionally negative words perceived by the right visual cortex
Number of subjects: 0
Study: 16203877

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg orally per week for twenty‐five weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no medication or placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 12548208

Group type: EXPERIMENTAL
Intervention: Endometritis/UGTI (defined as >or=5 neutrophils or >or=2 plasma cells, Neisseria gonorrhoeae or Chlamydia trachomatis upper genital tract infection)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Endometritis/UGTI
Number of subjects: 614
Study: 10860128

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 775
Study: 8657762

Group type: EXPERIMENTAL
Intervention: gel containing lysated keratinocyte cultures
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo-gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: fresh keratinocyte alloculture
Number of subjects: 20
Study: 2072138

Group type: EXPERIMENTAL
Intervention: IT MTX without cranial irradiation (MTX group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: IT MTX and 18 Gy cranial irradiation (18-Gy group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: IT MTX and 24 Gy cranial irradiation (24-Gy group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 77
Study: 6125203

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31335174

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional Occupational Therapy (TOT) intervention group
Number of subjects: 60
Study: 31104833

Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg every 2 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy (oral phosphate and active vitamin D)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 28135050

Group type: EXPERIMENTAL
Intervention: Symptom Care at Home (SCH)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 358
Study: 27192359

Group type: EXPERIMENTAL
Intervention: Smartphone text messaging education (10 text messages during hospitalization to first follow-up)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional textual and verbal information
Number of subjects: 61
Study: 23757034

Group type: EXPERIMENTAL
Intervention: Complicated appendicitis (Group 2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Noncomplicated appendicitis (Group 1)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonspecific abdominal pain (Group 3)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 49
Study: 22537763

Group type: EXPERIMENTAL
Intervention: Total estrogen metabolites
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 2/16α‐OH ratio
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 2/16α‐OHE(1) ratio
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 2‐OH pathway
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 16α‐OH pathway
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 4‐OH pathway, testosterone, and progesterone
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Size of the dense area
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Non-dense area
Number of subjects: 188
Study: 19079146

Group type: EXPERIMENTAL
Intervention: Flap on technique
Number of subjects: 8

Group type: COMPARATOR
Intervention: Flap off technique
Number of subjects: 8
Study: 17479609

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11185665

Group type: EXPERIMENTAL
Intervention: Fe2+ form of elemental iron, 7.5 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonionic trivalent iron (FeIII) complexed with polysaccharides, 7.5 mg daily
Number of subjects: 0
Study: 9124858

Group type: EXPERIMENTAL
Intervention: CP following oral administration of diltiazem (60 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CP following oral administration of nifedipine (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 12
Study: 1568367

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study: 3893511

Group type: EXPERIMENTAL
Intervention: Single dose of 2 g of sulfametopyrazine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ampicillin 250 mg thrice daily for 7 days
Number of subjects: 42
Study: 28419732

Group type: COMPARATOR
Intervention: Retosiban (6 mg/h infusion for 24 hours, followed by 12 mg/h infusion over the next 24 hours; preceded by a 6 mg loading dose over 5 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retosiban
Number of subjects: 0
Study: 26712227

Group type: EXPERIMENTAL
Intervention: Short-term rituximab maintenance (4 administrations every 2 months)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Long-term rituximab maintenance (maximum of 5 years or until disease progression)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Long-term rituximab maintenance
Number of subjects: 270

Group type: COMPARATOR
Intervention: Short-term rituximab maintenance
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270
Study: 24888381

Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg at night for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21941231

Group type: EXPERIMENTAL
Intervention: Vein Viewer
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard technique (Control)
Number of subjects: 115
Study: 19946776

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1,200 mg and vitamin D3 400 IU (10 microg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 18665021

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 160 mg IM
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 16037175

Group type: EXPERIMENTAL
Intervention: Lateral position (L group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Seated position (S group)
Number of subjects: 74
Study: 11922555

Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 microg i.v.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 38
Study: 10334683

Group type: EXPERIMENTAL
Intervention: HLA-DRB1-matched blood transfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8950666

Group type: EXPERIMENTAL
Intervention: EMG biofeedback closed loop traction control
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional open loop traction control
Number of subjects: 24
Study: 1835619

Group type: EXPERIMENTAL
Intervention: Sizofiran (SPG) administered with antitumour drugs
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (no sizofiran)
Number of subjects: 386
Study: 31828878

Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: RV septal pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of RV apical and RV septal pacing
Number of subjects: 50
Study: 29725846

Group type: EXPERIMENTAL
Intervention: 0.5% BISA mouthwash
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine + 0.5% BISA mouthwash
Number of subjects: 30
Study: 27628168

Group type: EXPERIMENTAL
Intervention: Physical activity promotion intervention (exercise program of 1-hour sessions twice a week for a year)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (received recommendations about an active lifestyle from their physicians)
Number of subjects: 160
Study: 25961184

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus olive oil
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus nuts
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 447
Study: 23392270

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily (high dose) over 3 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: 40 mg simvastatin daily (normal dose)
Number of subjects: 240
Study: 20674311

Group type: EXPERIMENTAL
Intervention: Resveratrol 30 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resveratrol 90 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resveratrol 270 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19